J. Jaime Caro, MDCM, FACP, FRCPC, is chief scientist at Evidera, professor in practice at London School of Economics, and adjunct professor of medicine, epidemiology, and biostatistics at McGill University.
Public health and economic priorities played a significant role in several US decisions regarding COVID-19, said J. Jaime Caro, MDCM, FACP, FRCPC. Ahead of a plenary session at ISPOR 2021, Caro spoke on the overlooked trade-offs that have occurred in weighing both priorities.
Transcript
You will be moderating a plenary session at ISPOR 2021 on the scope of health economics and outcomes research (HEOR) and its application in public health. Can you speak on public health investment and infrastructure and its impact on the nationwide response to COVID-19?
Precisely the reason that we decided to hold this plenary to see if we could shed some light on this very complex issue. The broad outlines of it, of course, are relatively simple, and I think most people in some way or another have become aware of it because it has touched them via their job, via what's available to them, via travel, and many other ways.
What the pandemic has done, I think, has brought to the fore on the one hand, epidemiology, epidemiologists are very happy, because all of a sudden they have brand recognition in terms of a profession. And it hasn't really brought health economics or economics very much into the limelight, even though it is clearly a major crisis economically.
I was a bit puzzled by this, a bit surprised that we're not seeing that challenge, that trade-off be addressed. I think partly because the health circumstances, the deaths, the shock of a pandemic that can kill hundreds of thousands of people, make many of them very, very sick, and so on, kind of put economics to the side and we don't really want to think about it, but it's clearly there.
Many decisions made in the United States, for example, were made essentially on economic grounds, maybe political to a point, but economic priorities overriding public health ones. And so what we're hoping to do in this plenary is to foster this debate on a more technical basis, by bringing in speakers who have been in the thick of it, and can speak to how they arrived at their decisions. I'm hoping that we will be able to draw them out and hear from them how they came to their trade-offs, how they made those trade-offs.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More